表紙
市場調查報告書

肺支氣管發育不良 : 開發中產品分析

Bronchopulmonary Dysplasia - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 213096
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
肺支氣管發育不良 : 開發中產品分析 Bronchopulmonary Dysplasia - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 76 Pages
簡介

肺支氣管發育不良是慢性疾病之一,是出生時接受人工呼吸器治療之早產兒中惡化的疾病之一。症狀有呼吸急促,心搏過速,更惡化的呼吸困難,皮膚發青等。原因有先天性心臟病,嚴重呼吸感染疾病/肺感染疾病等。

本報告提供肺支氣管發育不良治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肺支氣管發育不良概要

治療藥的開發

  • 開發中產品的概要
  • 肺支氣管發育不良:企業開發中的治療藥
  • 肺支氣管發育不良:企業開發中的產品

肺支氣管發育不良:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

肺支氣管發育不良的治療藥開發企業

  • Airway Therapeutics, Inc.
  • Chiesi Farmaceutici SpA
  • MediPost Co., Ltd.
  • Meridigen Biotech Co Ltd
  • Syntrix Biosystems, Inc.
  • Therabron Therapeutics, Inc.

藥物簡介

肺支氣管發育不良:暫停中的計劃

肺支氣管發育不良:開發中止的產品

肺支氣管發育不良:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12024IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2020, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchopulmonary Dysplasia - Overview
  • Bronchopulmonary Dysplasia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bronchopulmonary Dysplasia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
    • Advent Therapeutics Inc
    • Airway Therapeutics LLC
    • Ayuvis Research Inc
    • Chiesi Farmaceutici SpA
    • Insmed Inc
    • MediPost Co Ltd
    • Meridigen Biotech Co Ltd
    • Orphanix GmbH
    • Radikal Therapeutics Inc
    • Syntrix Biosystems Inc
    • Takeda Pharmaceutical Co Ltd
    • The Cell Factory BVBA
    • Trimunocor Ltd
    • United Therapeutics Corp
    • Windtree Therapeutics Inc
  • Bronchopulmonary Dysplasia - Drug Profiles
    • Aerosurf - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVR-48 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFMEV-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mecasermin rinfabate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • perfluorooctyl bromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pioglitazone + B-YL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Surfactant Associated Protein D Replacement for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
      • UMC-11901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UNEX-42 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchopulmonary Dysplasia - Dormant Projects
  • Bronchopulmonary Dysplasia - Discontinued Products
  • Bronchopulmonary Dysplasia - Product Development Milestones
    • Featured News & Press Releases
      • Aug 23, 2019: Medipost's Pneumostem gets FDA's fast-track designation
      • May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial
      • May 09, 2019: New phase 2b analysis suggests AEROSURF may reduce incidence and severity of bronchopulmonary dysplasia in preterm infants with RDS
      • Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.
      • Dec 10, 2018: New data from the AEROSURF phase 2b clinical program shows AEROSURF appears to reduce incidence and severity of Bronchopulmonary Dysplasia in preterm infants with RDS
      • Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia
      • Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer
      • May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM' for Treating Lung Disease
      • Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
      • Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
      • Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'
      • Feb 06, 2014: Stem cells to treat lung disease in preterm infants
      • Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
      • May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Orphanix GmbH, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by The Cell Factory BVBA, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Trimunocor Ltd, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by United Therapeutics Corp, H1 2020
  • Bronchopulmonary Dysplasia - Pipeline by Windtree Therapeutics Inc, H1 2020
  • Bronchopulmonary Dysplasia - Dormant Projects, H1 2020
  • Bronchopulmonary Dysplasia - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020